WSWattana Sukeepaisarnjaroen

Wattana Sukeepaisarnjaroen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wattana Sukeepaisarnjaroen has a total of 161 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Efficacy of Standard Triple Therapy With or Without Statin in Helicobacter pylori Eradication: A Randomized Double‐Blind Placebo‐Controlled Trial

    by Chitchai Rattananukrom, Punnaphol Waranophirun, Anupol Panitchote, Suda Vannaprasaht, Tanita Suttichaimongkol, Kookwan Sawadpanich, Apichart Sangchan, Wattana Sukeepaisarnjaroen, Pisaln Mairiang, Witsarut Manasirisuk

    Background and Aims: Standard triple therapy (STT) for Helicobacter pylori ( H. pylori ) infection has become suboptimal. Atorvastatin may improve eradication rates by promoting autophagy and reducing inflammation. This study aimed to evaluate the efficacy and safety of adjuvant atorvastatin with STT compared to STT alone for H. pylori eradication. Methods: In this randomized, placebo‐controlled trial, 138 treatment‐naïve patients with H. pylori infection were randomized to two groups. The intervention group ( n = 70) received a 14‐day regimen of omeprazole, amoxicillin, clarithromycin, and atorvastatin (40 mg once daily). The control group ( n = 68) received the same regimen with a matching placebo. The primary endpoint was H. pylori eradication, assessed by a urea breath test 4–6 weeks after treatment completion. Secondary endpoints included CYP2C19 and CYP3A4/5 genotypes, adverse events, and patient compliance. Results: The eradication rate in the intervention group was significantly higher than in the control group in both the per‐protocol (97.1% vs. 85.3%) and intention‐to‐treat (ITT) analyses (95.7% vs. 85.3%). The absolute risk difference for the ITT analysis was 10.4% (95% CI, 0.75 to 20.1; p = 0.03). The distribution of CYP2C19 and CYP3A4/5 genotypes was similar between groups. No clinically significant differences in adverse events were observed. Conclusion: Adjuvant therapy with atorvastatin combined with STT significantly improved H. pylori eradication rates without clinically significant adverse events. Further randomized controlled trials in diverse populations and with varying antibiotic resistance patterns are needed to better clarify the effects of statins on H. pylori treatment. Trial Registration: Thai Clinical Trial Registry, No. TCTR20220201001

  • Overall Survival and Treatment Outcomes in Patients With Primary Biliary Cholangitis: A 10-Year Single-Center Retrospective Cohort Study

    by Shunyapat Sirirattanakorn, Tanita Suttichaimongkol, Witsarut Manasirisuk, Kookwan Sawadpanich, Apichart Sangchan, Pisaln Mairiang, Wattana Sukeepaisarnjareon, Chitchai Rattananukrom


  • Top Cited Papers
    Open Access

    Five-year overall survival update from the HIMALAYA study of tremelimumab plus durvalumab in unresectable HCC

    by Lorenza Rimassa, Stephen L. Chan, Bruno Sangro, George Lau, Masatoshi Kudo, Maria Reig, Valeriy Breder, Min-Hee Ryu, Yuriy Ostapenko, Wattana Sukeepaisarnjaroen, et al.


  • Open Access

    Review of: "A Harmless Avian Vaccine Virus Could Be Developed into an Off-the-Shelf “Antibiotic” for Viruses"

    by Wattana Sukeepaisarnjaroen

    I agree with Dr. Tibor Bakacs to unlock the shelf-stocked R903/78 drug, but I am not sure about it and have the following concerns: 1. Naturally occurring infections of both types of viruses include hepatitis B and D infection, as well as hepatitis...

  • Open Access

    Outcomes in the Asian subgroup of the phase III randomised HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    by George Lau, Ghassan K. Abou-Alfa, Ann-Lii Cheng, Wattana Sukeepaisarnjaroen, Tu Van Dao, Yoon Koo Kang, Satheesh Chiradoni Thungappa, Masatoshi Kudo, Bruno Sangro, Robin Kate Kelley, et al.


  • Open Access

    The landscape of etiological patterns of hepatocellular carcinoma and intrahepatic cholangiocarcinoma in Thailand

    by Benjarath Pupacdi, Christopher A. Loffredo, Anuradha Budhu, Siritida Rabibhadana, Vajarabhongsa Bhudhisawasdi, Chawalit Pairojkul, Wattana Sukeepaisarnjaroen, Ake Pugkhem, Vor Luvira, Nirush Lertprasertsuke, et al.

    Thailand is among countries with the highest global incidence and mortality rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (iCCA). While viral hepatitis and liver fluke infections have been associated with HCC and iCCA, respectively, other environmental risk factors, overall risk factor commonality and combinatorial roles, and effects on survival have not been systematically examined. We conducted a TIGER‐LC consortium‐based population study covering all high‐incidence areas of both malignancies across Thailand: 837 HCC, 1474 iCCA, and 1112 controls (2011–2019) were comprehensively queried on lifelong environmental exposures, lifestyle, and medical history. Multivariate logistic regression and Cox proportional hazards analyses were used to evaluate risk factors and associated survival patterns. Our models identified shared risk factors between HCC and iCCA, such as viral hepatitis infection, liver fluke infection, and diabetes, including novel and shared associations of agricultural pesticide exposure (OR range of 1.50; 95% CI: 1.06–2.11 to 2.91; 95% CI: 1.82–4.63) along with vulnerable sources of drinking water. Most patients had multiple risk factors, magnifying their risk considerably. Patients with lower risk levels had better survival in both HCC (HR 0.78; 95% CI: 0.64–0.96) and iCCA (HR 0.84; 95% CI: 0.70–0.99). Risk factor co‐exposures and their common associations with HCC and iCCA in Thailand emphasize the importance for future prevention and control measures, especially in its large agricultural sector. The observed mortality patterns suggest ways to stratify patients for anticipated survivorship and develop plans to support medical care of longer‐term survivors, including behavioral changes to reduce exposures.


  • Open Access

    A new biomarker panel for differential diagnosis of cholangiocarcinoma: Results from an exploratory analysis

    by Bruno Köhler, Marta Bes, Henry Lik-Yuen Chan, Juan Ignacio Esteban, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, Tawesak Tanwandee, Satawat Thongsawat, Anika Mang, David Morgenstern, et al.

    Introduction: Diagnosis of cholangiocarcinoma (CCA) can be challenging due to unclear imaging criteria and difficulty obtaining adequate tissue biopsy. Although serum cancer antigen 19-9 and carcinoembryonic antigen have been proposed as potential diagnostic aids, their use remains limited by insufficient sensitivity and specificity. This exploratory analysis aimed to identify individual- and combinations of serum biomarkers to distinguish CCA from hepatocellular carcinoma (HCC) and chronic liver disease (CLD) controls using samples from a published study. Methods: This prospective, multicenter, case-control study included patients aged ≥18 years at high-risk of HCC. Serum and ethylene diamine tetraacetic acid-plasma samples were collected prior to any treatment and confirmed diagnosis of HCC or CCA. Fourteen biomarkers (measured by electrochemiluminescence immunoassays or enzyme-linked immunosorbent assays) were subjected to univariate analysis and 13 included in a multivariate analysis (per selected combinations and exhaustive search). Results: Overall, 55 CCA, 306 HCC, and 733 CLD control samples were analyzed. For distinguishing CCA from HCC, alpha-fetoprotein and matrix metalloproteinase-2 (MMP-2) showed the best individual performance (area under the curve (AUC) 86.6% and 84.4%, respectively); tissue inhibitor of metalloproteinase-1 (TIMP-1) was most able to distinguish CCA from CLD (AUC 94.5%) and from HCC + CLD (AUC 88.6%). The combination of MMP-2 and TIMP-1 was the best-performing two-marker panel, with AUC >90% for all comparisons. Conclusion: MMP-2 and TIMP-1 are promising biomarkers that could support differential diagnosis of CCA. Incorporating these assays into the diagnostic algorithm could provide additional diagnostic information in a non-invasive, rapid manner, and could supplement existing diagnostic methods.


  • First-in-human randomized study of RNAi therapeutic RG6346 for chronic hepatitis B virus infection

    by Edward J. Gane, Won Kim, Tien Huey Lim, Pisit Tangkijvanich, Jung-Hwan Yoon, William Sievert, Wattana Sukeepaisarnjaroen, Alexander J. Thompson, Vedran Pavlovic, Bernadette Surujbally, et al.


  • Open Access

    Validation of prognostic scores predicting mortality in acute liver decompensation or acute-on-chronic liver failure: A Thailand multicenter study

    by Tongluk Teerasarntipan, Kessarin Thanapirom, Sakkarin Chirapongsathorn, Tanita Suttichaimongkol, Naichaya Chamroonkul, Chalermrat Bunchorntavakul, Sith Siramolpiwat, Siwaporn Chainuvati, Abhasnee Sobhonslidsuk, Apinya Leerapun, et al.

    Background & objectives: Cirrhosis patients with worsening of the liver function are defined as acute decompensation (AD) and those who develop extrahepatic organ failure are defined as acute-on-chronic liver failure (ACLF). Both AD and ACLF have an extremely poor prognosis. However, information regarding prognostic predictors is still lacking in Asian populations. We aimed to identify prognostic factors for 30-day and 90-day mortality in cirrhosis patients who develop AD with or without ACLF. Methods: We included 9 tertiary hospitals from Thailand in a retrospective observational study enrolling hospitalized cirrhosis patients with AD. ACLF was diagnosed according to the EASL-CLIF criteria, which defined as AD patients who have kidney failure or a combination of at least two non-kidney organ failure. Outcomes were clinical parameters and prognostic scores associated with mortality evaluated at 30 days and 90 days. Results: Between 2015 and 2020, 602 patients (301 for each group) were included. The 30-day and 90-day mortality rates of ACLF vs. AD were 57.48% vs. 25.50% (p<0.001) and 67.44% vs. 32.78% (p<0.001), respectively. For ACLF patients, logistic regression analysis adjusted for demographic data, and clinical information showed that increasing creatinine was a predictor for 30-day mortality (p = 0.038), while the CLIF-C OF score predicted both 30-day (p = 0.018) and 90-day (p = 0.037) mortalities, achieving the best discriminatory power with AUROCs of 0.705 and 0.709, respectively. For AD patients, none of the parameters was found to be significantly associated with 30-day mortality, while bacterial infection, CLIF-AD score and Child-Turcotte-Pugh score were independent parameters associated with 90-day mortality, with p values of 0.041, 0.024 and 0.024. However, their predictive performance became nonsignificant after adjustment by multivariate regression analysis. Conclusions: Regarding Thai patients, the CLIF-C OF score was the best predictor for 30-day and 90-day mortalities in ACLF patients, while appropriate prognostic factors for AD patients remained inconclusive.


  • Open Access

    Characteristics of Drug-induced Liver Injury in Chronic Liver Disease: Results from the Thai Association for the Study of the Liver (THASL) DILI Registry

    by Sakkarin Chirapongsathorn, Wattana Sukeepaisarnjaroen, Sombat Treeprasertsuk, Roonguedee Chaiteerakij, Pichaporn Surawongsin, Chanunta Hongthanakorn, Sith Siramolpiwat, Naichaya Chamroonkul, Chalermrat Bunchorntavakul, Watcharasak Chotiyaputta, et al.

    The impact of drug-induced liver injury (DILI) on patients with chronic liver disease (CLD) is unclear. There are few reports comparing DILI in CLD and non-CLD patients. In this study, we aimed to determine the incidence and outcomes of DILI in patients with and without CLD.